Skip to content
Screener

Precigen PGEN Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$135M-1.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$243M-3.5%
Gilead Sciences logo
Gilead SciencesGILD
$231M+2.7%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$8.27M-32.1%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$17.16M+54.2%
Regenxbio logo
RegenxbioRGNX
$9.05M+4.6%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$2.47B+358%
Enterprise value$2.56B+382%
P/S93.2×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Precigen’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356090-26-000017
(Amounts in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Depreciation and amortization1,099629
Change in fair value of warrant liabilities32,481
Amortization of discounts on investments, net(369)(706)
Stock-based compensation expense3,0062,677
Shares issued as payment for services526527
Accretion of debt discount and amortization of deferred financing costs345
Changes in operating assets and liabilities:
Receivables:

Item 1. Condensed Consolidated Financial Statements

FAQ

What is Precigen's stock-based comp?
Precigen (PGEN) reported stock-based comp of $3.01M in Q1 2026.
How has Precigen's stock-based comp changed year-over-year?
Precigen's stock-based comp increased by 12.3% year-over-year, from $2.68M to $3.01M.
What is the long-term trend for Precigen's stock-based comp?
Over 4 years (2021 to 2025), Precigen's stock-based comp has grown at a -6.0% compound annual growth rate (CAGR), from $13.9M to $10.87M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Precigen's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude